LG 203003
Alternative Names: LG-203003; LR-19018Latest Information Update: 03 Aug 2022
At a glance
- Originator LG Chem
- Class Hepatoprotectants
- Mechanism of Action Diacylglycerol O-acyltransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Non-alcoholic steatohepatitis
Most Recent Events
- 29 Jul 2022 LG 203003 is available for licensing as of 29 Jul 2022. https://innovation.lgchem.com/ResearchDevelopment/Partnership.do
- 14 Jul 2022 Phase-I clinical trials in Non-alcoholic steatohepatitis in USA (unspecified route)
- 14 Jul 2022 Preclinical trials in Non-alcoholic steatohepatitis in USA (unspecified route) (Before July 2022)